Skip to main content
Fig. 1 | Translational Medicine Communications

Fig. 1

From: Safety and efficacy of autologous non-hematopoietic enriched stem cell nebulization in COVID-19 patients: a randomized clinical trial, Abu Dhabi 2020

Fig. 1

Patient allocation during the SENTAD-COVID Study. Legend: Four initially screened patients were excluded before randomization because 2 had been previously diagnosed with malignant diseases, and 2 were previously included in other clinical trials. After randomization, data from 4 additional patients were not analyzed. 2 patients in the control group had data error identifications. 2 patients were not followed in the PB-NHESC-C group: 1 was released from the hospital, and the other unfortunately died before the initial day of treatment

Back to article page